Abstract There are currently limited data on the epidemiology, clinical manifestations and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplant and cellular therapy patients. Given the experience… Click to show full abstract
Abstract There are currently limited data on the epidemiology, clinical manifestations and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplant and cellular therapy patients. Given the experience with other respiratory viruses, we anticipate patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity and guidance provided in this document may change as new information becomes available.
Journal Title: Biology of Blood and Marrow Transplantation
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!